Elevation Oncology Inc 2024年度报告

For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For The Transition Period FromTo Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes ☐ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes ☐No ☐ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days. Yes ☐No ☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☐No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 ofthe Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its auditreport. ☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflectthe correction of an error to previously issued financial statements. ☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any ofthe registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☐ The aggregate market value of Common Stock held by non-affiliates of the registrant computed by reference to the price of the registrant’s Common Stock as of June30, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $135.2 million (based on the last reported saleprice on the Nasdaq Global Select Market as of such date). As of February 28, 2025, there were 59,215,795 shares of the registrant’s common stock, par value$0.0001 per share, outstanding. Documents Incorporated by Reference The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the endof the registrant’s fiscal year ended December 31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Reporton Form 10-K to the extent stated herein. TABLE OF CONTENTS PART I Item 1. BusinessItem 1A. Risk FactorsItem 1B. Unresolved Staff CommentsItem 1C. CybersecurityItem 2. PropertiesItem 3. Legal ProceedingsItem 4. Mine Safety Disclosures 5288484868686PART IIItem 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities86Item 6. [Reserved]87Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations88Item 7A. Quantitative and Qualitative Disclosures About Market Risk101Item 8. Financial Statements and Supplementary Data101Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure128Item 9A. Controls and Procedures128Item 9B. Other Information129Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections129PART IIIItem 10. Directors, Executive Officers and Corporate Governance129Item 11. Executive Compensation129Item 12. Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters129Item 13. Certain Relationships and Related Transactions, and Director Independence130Item 14. Principal Accountant’s Fees and Services130PART IVItem 15. Exhibits and Financial Statement Schedules130Item 16. Form 10-K Summary133SIGNATURES134 Throughout this Annual Report on Form 10-K (the “Annual Report”), the “Company”, “Elevation”, “ElevationOncology”, “we”, “us”,